Press Room

Event

AAPS 2023 PharmSci 360

Start
Sunday, October 22, 2023
End
Wednesday, October 25, 2023
Location: Orlando, USA
Booth Number: 2429

 

Visit Hovione’s booth at AAPS PharmSci 360 next October 22-23 in Orlando and meet our team of experts.

The AAPS PharmSci 360 Annual Meeting is organized by the American Association of Pharmaceutical Scientists (AAPS). The event provides a platform for pharmaceutical scientists from academia, industry, government, and other institutions worldwide to exchange knowledge and discuss the latest advancements in the field.

Schedule a meeting with our experts to learn how our end-to-end solutions in one site can support your projects.

Our experts traveling to Orlando will present the following posters:

 

HOVIONE POSTERS

 

Monday, October 23, 2023

Manufacturing and Analytical Characterization – Chemical

Impact of Alternative Lubricants on Tablet Parameters Approaching the Over-Lubrication Problems in Continuous Direct Compression Processes

  • 1:30 PM – 2:30 PM ET
  • Presenting: Nuno Branco, Ph.D.
  • Main Author: Tomas Santos, B.S.

     

Formulation and Delivery – Biomolecular

Hot and Cold Formulation of Biologics for the Optimization of Drying Technologies

  • 3:30 PM – 4:30 PM ET
  • Presenting: Paulo Lino, Ph.D.
  • Main Author: Susana Farinha, M.Sc.

     

Tuesday, October 24, 2023

Formulation and Delivery – Biomolecular

Analytical Characterization for Nucleic Acid Therapy: A Case Study

  • 12:30 PM – 1:30 PM ET
  • Main Author; Presenting: Rute Mota, M.Sc.

     

Formulation and Delivery – Chemical

Beyond Conventional Boundaries: New Excipients for ASD Formulation

  • 2:30 PM – 3:30 PM ET
  • Presenting; Main Author: Francisco Tavares, M.Sc.

 

Wednesday, October 25, 2023

Formulation and Delivery – Chemical

Dispersome® a Viable Alternative toward Enhanced Drug Load and Bioavailability

  • 9:30 AM – 10:30 AM ET
  • Presenting: Francisco Tavares, M.Sc.
  • Main Author: Maria Paisana, Ph.D.

     

Manufacturing and Analytical Characterization – Chemical

Challenges in Nitrosamine Determination for Pharmaceutical Products: An Analytical Perspective

  • 10:30 AM – 11:30 AM ET
  • Presenting; Main Author: Marco Galésio, Ph.D.

     

EXTRA PRESENTATION - Special Poster Collection

 

Tuesday, October 24, 2023 2:30 PM – 3:30 PM ET 

Location: Poster Forum #7; Exhibit Hall West A4-B3

 

Manufacturing and Analytical Characterization – Chemical

Impact of Alternative Lubricants on Tablet Parameters Approaching the Over-Lubrication Problems in Continuous Direct Compression Processes

  • Presenting: Nuno Branco, Ph.D.
  • Main Author: Tomas Santos, B.S.

     

Don’t miss the chance to speak with our team. Visit us at Booth #2429.

See you in Orlando.

 

 

Let’s discuss your project together.

schedule a meeting
https://go.hovione.com/l/47122/2014-08-06/9grc



 

 

 

Schedule a meeting with our experts.

 

Find more about AAPS PharmSci 360.

Also in the Press Room

See All

Aim to accelerate drug development and production with new technologies. By: Charlie Sternberg Hovione, an international integrated pharmaceutical development and manufacturing organization, and Microinnova Engineering, a leader in continuous process intensification, have partnered to advance the development of multi-purpose, plug-and-play modular equipment for flow chemistry. The companies will work together to test Microinnova’s modular manufacturing equipment, which is designed to offer greater flexibility, easier scalability, enhanced efficiency, and sustainable practices in active ingredient production, in an industrial setting. Together, the companies aim to accelerate process development, facilitate a seamless transition from lab to large-scale manufacturing, and ultimately reduce the time to market for pharmaceutical customers. “This collaboration with Microinnova underscores Hovione’s commitment to innovation in pharmaceutical manufacturing, with flow chemistry playing an important role in our long-term drug substance strategy,” said Dr. Jean-Luc Herbeaux, CEO of Hovione. “This partnership will allow us to shape and validate emerging continuous manufacturing technologies, which can potentially accelerate drug development and production.” Dr. Dirk Kirschneck, Founder and Strategic Director at Microinnova, added, “This partnership reflects our shared vision to deliver modular manufacturing technologies that support pharmaceutical innovation and manufacturing excellence. We are proud to join forces with Hovione to showcase the capabilities of our next-generation modular equipment in a dynamic CDMO environment, demonstrating its versatility for multi-purpose manufacturing.”   Read the full article on ContractPharma.com  

Press Clipping
Contract Pharma, 24 September 2025

Hovione, Microinnova Partner to Test Modular Manufacturing Equipment

Sep 24, 2025

Hovione is a global contract development and manufacturing organization (CDMO) company founded in Portugal in 1959. With approximately 2,400 team members worldwide, the company provides comprehensive services for drug substances, drug intermediates, and drug products in countries around the world. Japan in particular plays a very important role in Hovione's global strategy, and in 2017 it established a Japanese subsidiary in Osaka. The company plans to actively invest in further strengthening its organization and recruiting personnel. With development labs strategically located in Lisbon, Portugal, and New Jersey, USA, Hovione consistently provides superior solutions tailored to complex pharmaceutical challenges. Hovione is recognized globally for its scientific excellence, technological innovation, and customer-centric and integrated approach. Leveraging cutting-edge capabilities in chemical synthesis, particle engineering, and formulation development, the company supports its partners throughout the entire pharmaceutical life cycle.   Read the full article in Japanese Read the article translated in English   Visit the Yakuji Nippo online      

Press Clipping
Yakuji Nippo Magazine, 2 July 2025

Solving Complex Pharmaceutical Challenges

Jul 10, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping
Pharmiweb.com, 25 June 2025

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025

Also in Events

See All